Veracyte
Develops molecular tests that guide cancer diagnosis, treatment, and recurrence monitoring.
$44.20
After-hours close+0.87 (+2.01%)
At close$43.33(−4.24%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 119.53%Insiders 1.79%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 79.79M · Float —
Institutions13F, as of Jun 30, 2026
378 holders · 95.38M shares · 79 new positions · 207 increased · 124 reduced · 43 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.49M | 16.90% | +313.8K | Aug 7, 2026 |
| FMR LLC | 7.70M | 9.65% | −61.1K | Aug 13, 2026 |
| Artisan Partners Limited Partnership | 5.54M | 6.94% | +42.0K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 4.72M | 5.91% | +271.5K | Aug 13, 2026 |
| State Street Corp | 4.70M | 5.89% | −345.5K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 3.59M | 4.50% | +61.7K | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 2.83M | 3.54% | −54.6K | Aug 11, 2026 |
| First Trust Advisors LP | 2.51M | 3.14% | +390.9K | Aug 11, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 15.20% | 11.93M | 13G | Aug 1, 2025 ↗ |
| FMR LLC | 10.10% | 8.06M | 13G | Jun 5, 2026 ↗ |
| Artisan Partners Limited Partnership | 8.50% | 6.60M | 13G | Feb 12, 2025 ↗ |
| Artisan Partners Asset Management Inc. | 6.90% | 5.50M | 13G | May 13, 2026 ↗ |
| State Street Corporation | 6.30% | 5.04M | 13G | May 12, 2026 ↗ |
| Vanguard Portfolio Management | 5.67% | 4.51M | 13G | Apr 29, 2026 ↗ |
| Vanguard Capital Management | 5.20% | 4.13M | 13G | Apr 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Marc Stapley | director, officer: Chief Executive Officer | 440.5K | 0.55% | Jun 4, 2026 |
| Rebecca Chambers | officer: Chief Financial Officer | 173.3K | 0.22% | Jun 4, 2026 |
| Phillip G. Febbo | officer: Chief Scientific & Med Officer | 149.8K | 0.19% | Jun 4, 2026 |
| Annie McGuire | officer: EVP, General Counsel | 137.2K | 0.17% | Jun 4, 2026 |
| John Leite | officer: Global Chief Commercial Off | 132.3K | 0.17% | Jun 4, 2026 |
| Robert S. Epstein | director | 57.7K | 0.07% | Jun 15, 2026 |
| Eliav Barr | director | 56.5K | 0.07% | Jun 15, 2026 |
| Muna Bhanji | director | 44.6K | 0.06% | Jun 15, 2026 |
| Kevin Richard Haas | officer: Chief Dev and Tech Officer | 44.2K | 0.06% | Apr 14, 2026 |
| Jonathan Wygant | officer: VP, Chief Accounting Officer | 44.1K | 0.06% | Jun 4, 2026 |
12 ten-percent owners hold 9.35M shares by Form 4, outside the officers-and-directors figure above · 14 people have not refiled in the last 18 months (4.07M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 18, 2026 | Karin Easthamdirector | Sale · 2 lots | 3,729 | $52.89 | 15,097 |
| Jun 4, 2026 | John Leiteofficer: Global Chief Commercial Off | Sale | 13,975 | $50.07 | 132,305 |
| Jun 4, 2026 | Marc Stapleydirector, officer: Chief Executive Officer | Sale | 138,051 | $50.12 | 440,494 |
| Jun 4, 2026 | Rebecca Chambersofficer: Chief Financial Officer | Sale · 2 lots | 3,561 | $49.73 | 173,280 |
| Jun 4, 2026 | Annie McGuireofficer: EVP, General Counsel | Sale · 2 lots | 3,176 | $49.76 | 137,240 |
| May 22, 2026 | Jonathan Wygantofficer: VP, Chief Accounting Officer | Sale | 24,000 | $45.40 | 45,434 |
| May 20, 2026 | Robert S. Epsteindirector | Sale | 10,000 | $44.01 | 52,446 |
| May 6, 2026 | Annie McGuireofficer: SVP, General Counsel | Sale · 2 lots | 10,204 | $39.03 | 143,708 |
| Mar 4, 2026 | Annie McGuireofficer: SVP, General Counsel | Sale · 2 lots | 6,658 | $35.55 | 94,706 |
| Mar 4, 2026 | John Leiteofficer: Chief Commercial Officer-CLIA | Sale | 5,260 | $35.19 | 107,580 |
CongressHouse and Senate disclosures
Not reported.